Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysis

OBJECTIVE: This review aimed to comprehensively analyze the safety and efficacy of erdafitinib in treating advanced and metastatic urothelial carcinoma and other solid tumors. METHODS: PubMed, Embase, and ClinicalTrials.gov were searched until 10 February 2022. The safety outcome as adverse events a...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Xinyi, Wang, Hang, Deng, Junyue, Yao, Minghe, Zou, Xiuhe, Zhang, Fan, Ma, Xuelei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909824/
https://www.ncbi.nlm.nih.gov/pubmed/36776367
http://dx.doi.org/10.3389/fonc.2022.907377

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909824/
https://www.ncbi.nlm.nih.gov/pubmed/36776367
http://dx.doi.org/10.3389/fonc.2022.907377

Ejemplares similares